In health care crises, researchers can avoid waiting for clinical trial results by using data from health care systems to analyze the effectiveness of treatments for COVID-19 and other illnesses.
Articles on Anti-viral monoclonal antibodies
Displaying all articles
Antiretroviral therapies for HIV, while extremely effective, need to be taken daily for life. Designing antibody treatments that need to be taken only once could improve compliance and reduce drug resistance.
Evusheld is an antibody drug from AstraZeneca intended to help prevent COVID-19 infection for immunocompromised and other vulnerable patients.
Although treatments for Ebola have helped many people overcome this deadly disease, the virus can persist in the brain and cause a lethal relapse.
Merck and Pfizer both have oral antiviral pills under review by the FDA. Such treatments could help turn the tide of the pandemic.
Top contributors
-
Assistant Professor of Infectious Diseases, University of Virginia
-
Principal Investigator of Infectious Diseases, U.S. Army Medical Research Institute of Infectious Diseases
-
Clinical Assistant Professor of Medicine, University of Pittsburgh
-
Vice President of Clinical Analytics, University of Pittsburgh
-
Associate Professor of Medicine, Epidemiology and Clinical and Translational Science, University of Pittsburgh
-
Professor of Pathology, Vice-chair for Research, University of Miami